Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2013 1
2015 1
2017 1
2018 2
2019 4
2020 8
2021 8
2022 9
2023 8
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

41 results

Results by year

Filters applied: . Clear all
Page 1
Risk and Response-Adapted Treatment in Multiple Myeloma.
Cazaubiel T, Mulas O, Montes L, Schavgoulidze A, Avet-Loiseau H, Corre J, Perrot A. Cazaubiel T, et al. Among authors: mulas o. Cancers (Basel). 2020 Nov 24;12(12):3497. doi: 10.3390/cancers12123497. Cancers (Basel). 2020. PMID: 33255368 Free PMC article. Review.
Health-Related Quality of Life Assessment in Patients with Myelodysplastic Syndromes: Evidence from Randomized Clinical Trials.
Giesinger JM, La Nasa G, Sparano F, Angermeyer M, Morelli E, Mulas O, Efficace F, Caocci G. Giesinger JM, et al. Among authors: mulas o. Clin Pract Epidemiol Ment Health. 2021 Dec 31;17(1):307-314. doi: 10.2174/1745017902117010307. eCollection 2021. Clin Pract Epidemiol Ment Health. 2021. PMID: 35444708 Free PMC article. Review.
Determinants of frontline tyrosine kinase inhibitor choice for patients with chronic-phase chronic myeloid leukemia: A study from the Registro Italiano LMC and Campus CML.
Tiribelli M, Latagliata R, Breccia M, Capodanno I, Miggiano MC, Cavazzini F, Bucelli C, Attolico I, Crescenzi SL, Russo S, Annunziata M, Sorà F, Bonifacio M, Mulas O, Loglisci G, Maggi A, Binotto G, Crisà E, Scortechini AR, Leporace AP, Sancetta R, Murgano P, Abruzzese E, Stagno F, Rapezzi D, Luzi D, Vincelli I, Bocchia M, Fava C, Malato A, Crugnola M, Pizzuti M, Lunghi F, Galimberti S, Dalmazzo M, Fanin R, Scalzulli E, Foà R, Iurlo A, Saglio G, Specchia G. Tiribelli M, et al. Among authors: mulas o. Cancer. 2023 Sep 1;129(17):2637-2644. doi: 10.1002/cncr.34923. Epub 2023 Jun 24. Cancer. 2023. PMID: 37354090
Dihydroorotate dehydrogenase inhibition reveals metabolic vulnerability in chronic myeloid leukemia.
Houshmand M, Vitale N, Orso F, Cignetti A, Molineris I, Gaidano V, Sainas S, Giorgis M, Boschi D, Fava C, Passoni A, Gai M, Geuna M, Sora F, Iurlo A, Abruzzese E, Breccia M, Mulas O, Caocci G, Castagnetti F, Taverna D, Oliviero S, Pane F, Lolli ML, Circosta P, Saglio G. Houshmand M, et al. Among authors: mulas o. Cell Death Dis. 2022 Jun 30;13(6):576. doi: 10.1038/s41419-022-05028-9. Cell Death Dis. 2022. PMID: 35773274 Free PMC article.
The new Systematic Coronary Risk Evaluation (SCORE2 and SCORE2-OP) estimates the risk of arterial occlusive events in chronic myeloid leukemia patients treated with nilotinib or ponatinib.
Mulas O, Abruzzese E, Luciano L, Iurlo A, Attolico I, Castagnetti F, Galimberti S, Bonifacio M, Annunziata M, Gozzini A, Orlandi EM, Stagno F, Binotto G, Pregno P, Fozza C, Loi M, Trawinska MM, De Gregorio F, Cattaneo D, Albano F, Iezza M, Baratè C, Scaffidi L, Elena C, Giai V, Scalzulli E, Breccia M, La Nasa G, Caocci G. Mulas O, et al. Ann Hematol. 2024 Feb;103(2):427-436. doi: 10.1007/s00277-023-05556-0. Epub 2023 Nov 28. Ann Hematol. 2024. PMID: 38012435 Free PMC article.
41 results